Mouse Model of Human Papillomavirus Pathogenesis

人乳头瘤病毒发病机制的小鼠模型

• 批准号: 10590721
• 负责人: PAUL F. LAMBERT
• 金额: $ 45.92万
• 依托单位: TUFTS UNIVERSITY BOSTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10590721
• 关键词: Address; Animal Model; Animals; Anogenital cancer; Antiviral Therapy; Area; Binding; Binding Sites; Biological Assay; C-terminal; Cancer Etiology; Cell Cycle; Cells; Cervix carcinoma; Chronic; Complement; Cutaneous; Development; Epidermodysplasia Verruciformis; Epithelium; Etiology; Genetic Transcription; Genetically Engineered Mouse; Genome; HPV E7; Head and Neck Cancer; House mice; Human; Human Papilloma Virus-Related Malignant Neoplasm; Human Papillomavirus; Human papilloma virus infection; Human papillomavirus 18; Hyperplasia; Immune signaling; Immunocompetent; Immunocompromised Host; Immunodeficient Mouse; Immunosuppression; India; Infection; Inherited; Laboratories; Laboratory mice; Length; Lesion; Life Cycle Stages; Link; MADH2 gene; Malignant Neoplasms; Marketing; Mediating; Modeling; Mouse Strains; Mus; Mutate; Oncogenic; Organ Transplantation; Papilloma; Papillomavirus; Papillomavirus Infections; Papillomavirus Transforming Protein E6; Pathogenesis; Pathway interactions; Patients; Population; Preventive vaccine; Proteins; Proteomics; RB1 gene; Reporting; Research; Role; Signal Pathway; Signal Transduction; Signal Transduction Pathway; Signaling Protein; Skin; Skin Cancer; Source; Squamous Epithelium; Stimulator of Interferon Genes; Sun Exposure; TRIM25 gene; Testing; Transforming Growth Factor beta; Transgenic Mice; UV Radiation Exposure; Ultraviolet Therapy; Vaccination; Vaccines; Viral; Viral Pathogenesis; Withdrawal; Work; carcinogenesis; cellular targeting; cofactor; combat; experimental study; high risk; high risk population; human model; in vivo; insight; keratinocyte differentiation; mouse model; mucosal site; mutant; programs; retinoblastoma tumor suppressor; skin disorder; skin lesion; skin squamous cell carcinoma; viral carcinogenesis

Human papillomavirus (HPV) infections cause approximately 5% of all human cancers. A group of “high-risk” alpha-HPVs are etiologic agents of cervical carcinoma, other anogenital cancers and as well as head and neck cancers. The beta-HPVs cause cutaneous squamous cell carcinomas (cSCCs) in patients with a rare hereditary skin disorder, epidermodysplasia verruciformis (EV), and in the rapidly growing population of organ-transplant and other chronically immunosuppressed patients. The gamma-HPVs have also been detected in cSCCs. Even though prophylactic vaccines that protect from infections with most cancer-associated alpha-HPVs are on the market, US vaccination rates have remained low, and because cancers arise years to decades after the initial infection, vaccination will not have an immediate impact on HPV cancer rates. Moreover, these vaccines do not offer protection from beta- and gamma-HPV infections and, hence, they will not impact cSCCs triggered by these HPVs. The E6 and E7 proteins encoded by the cancer-associated alpha- and beta-HPVs have oncogenic activities and function by binding to and functionally subverting host cellular signaling proteins. Because HPVs do not replicate in heterologous hosts, there have only been very few studies that probed the relevance of papillomavirus E6 and E7 cellular targets for viral pathogenesis and carcinogenesis in vivo. The discovery of Mus musculus Papillomavirus 1 (MmuPV1), which infects common laboratory mouse strains, finally allows papillomavirus pathogenesis and carcinogenesis studies in vivo and in a genetically tractable host. This proposal leverages the expertise of the Lambert group who has established an MmuPV1 infection/pathogenesis model for cutaneous and mucosal sites and the Munger lab who has identified MmuPV1 E6- and E7-associated cellular proteins and validated many of these interactions in cell-based assays. Our proposal is based on the hypothesis that MmuPV1 is a model to investigate HPV pathogenesis and carcinogenesis, and these insights will be key to identifying targets for antiviral therapy. We will investigate the importance of MmuPV1 E6 inhibiting NOTCH and TGF-beta signaling, and E7 subverting the retinoblastoma tumor suppressor RB1, as well as E6 and E7 mediated subversion of innate immune signaling by the RIG-I/MAVS and cGAS/STING, respectively, for cutaneous pathogenesis and carcinogenesis.

人类乳头瘤病毒（HPV）感染导致大约5%的人类癌症。一组“高风险”α -人乳头状瘤病毒是宫颈癌、其他肛门生殖器癌症以及头颈部癌症的病因。在一种罕见的遗传性皮肤病，疣状表皮发育不良（EV）患者，以及快速增长的器官移植和其他慢性免疫抑制患者中，β - hpv可引起皮肤鳞状细胞癌（cSCCs）。在cSCCs中也检测到γ - hpv。尽管市场上有预防大多数癌症相关的甲型HPV感染的预防性疫苗，但美国的疫苗接种率仍然很低，而且由于癌症在初次感染后几年到几十年才会发生，因此疫苗接种不会对HPV癌症发病率产生直接影响。此外，这些疫苗不能预防-和- hpv感染，因此，它们不会影响由这些hpv引发的cSCCs。由癌症相关的α - hpv和β - hpv编码的E6和E7蛋白通过结合并在功能上破坏宿主细胞信号蛋白而具有致癌活性和功能。由于hpv不能在异源宿主中复制，因此只有很少的研究探讨了乳头瘤病毒E6和E7细胞靶点与体内病毒发病和致癌的相关性。感染普通实验室小鼠株的小家鼠乳头瘤病毒1 （MmuPV1）的发现，最终使乳头瘤病毒在体内和遗传易感宿主中的发病机制和癌变研究成为可能。该提案利用了Lambert小组的专业知识，他们已经建立了皮肤和粘膜部位的MmuPV1感染/发病机制模型，Munger实验室已经确定了MmuPV1 E6和e7相关的细胞蛋白，并在基于细胞的分析中验证了许多这些相互作用。我们的建议是基于假设MmuPV1是研究HPV发病机制和致癌作用的模型，这些见解将是确定抗病毒治疗靶点的关键。我们将研究mupv1 E6抑制NOTCH和tgf - β信号，E7破坏视网膜母细胞瘤肿瘤抑制因子RB1，以及E6和E7分别通过RIG-I/MAVS和cGAS/STING介导的先天免疫信号的破坏在皮肤发病和癌变中的重要性。